Korea Research Institute of Chemical Technology (KRICT) has synthesized novel pyrimidine-2,4-diamine derivatives acting as EGFR (HER1; erbB1) and/or HER2 (erbB2) (mutant) inhibitors reported to be useful for the treatment of cancer.
Splicing junctions between transposable elements and regular exons are transcribed, and can serve as targets for anticancer therapies, researchers from the Institut Curie and Mnemo Therapeutics SAS reported in a pair of papers published in Science Immunology on Feb. 3, 2023.
Prelude Therapeutics Inc. has divulged proteolysis-targeting chimeric (PROTAC) compounds comprising a Von Hippel-Lindau E3 ubiquitin ligase (VHL)-binding moiety covalently linked to a SMARCA2- or SMARCA4-targeting moiety through a linker reported to be useful for the treatment of cancer.
Wigen Biomedicine Technology (Shanghai) Co. Ltd. has disclosed fused ring compounds acting as Wee1-like protein kinase (Wee1) inhibitors reported to be useful for the treatment of cancer.
Previous studies have revealed that the microbiome plays a role in the development and progression of some cancers and gut microbiome has been linked with immune homeostasis as well as antitumor immune responses. In the current study, scientists at the University of California, Davis aimed to evaluate the intratumoral microbiome in patients with nonmetastatic soft tissue sarcoma (STS) undergoing neoadjuvant radiotherapy (RT) and surgery.
Atreca Inc. and Xencor Inc. have mutually selected the first program from their strategic collaboration combining an Atreca-discovered antibody with Xencor's Xmab bispecific Fc domain and a cytotoxic T-cell binding domain (CD3).
Harbour Biomed Ltd. has received IND clearance by the FDA to initiate clinical trials in the U.S. with HBM-1022, a monoclonal antibody generated from Harbour's integrated G protein-coupled receptor (GPCR) platform. The antibody can enhance antitumor immunity by depleting CCR8 positive regulatory T cells, activating effector T cells.
Wigen Biomedicine Technology (Shanghai) Co. Ltd. has described 1,2,4-triazolone derivatives acting as dihydroorotate dehydrogenase (DHODH) inhibitors reported to be useful for the treatment of solid tumors and hematologic blood cancer.
Humanwell Healthcare (Group) Co. Ltd. has identified transcriptional enhancer factor (TEAD) inhibitors reported to be useful for the treatment of cancer.
Shanghai Aryl Pharmtech Co. Ltd. and Zhejiang Hisun Pharmaceutical Co. Ltd. have divulged trideuteromethyl-substituted pyrazino pyrazino quinolinone derivatives acting as deuterated GTPase KRAS (mutant) inhibitors reported to be useful for the treatment of cancer.
RSS
